Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cnv2197944. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 8/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cnv2197944 SCHEMBL18652790 | 0.99 | HSD11B1 (0.48) | HSD11B1ALDH1A1TRPV1GAAKMT2A | |
| Cnv2197944 SCHEMBL1429576 | 0.99 | HSD11B1 (0.48) | HSD11B1ALDH1A1TRPV1GAAKMT2A | |
| Cnv2197944 SCHEMBL12965609 | 0.99 | HSD11B1 (0.48) | HSD11B1ALDH1A1TRPV1GAAKMT2A | |
| Cnv2197944 SCHEMBL1429628 | 0.95 | HSD11B1 (0.46) | HSD11B1ALDH1A1TRPV1GAAKMT2A | |
| SCHEMBL1429856 | 0.89 | HSD11B1 (0.46) | HSD11B1TRPV1GAAKMT2A | |
| SCHEMBL13373122 | 0.88 | TSHR (0.50) | HSD11B1ALDH1A1GAAKMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL1430239 | 0.88 | GAA (0.41) | HSD11B1TRPV1GAAEPHX2 | |
| Hydrochloric Acid SCHEMBL1947130 | 0.88 | HSD11B1 (0.47) | HSD11B1ALDH1A1TRPV1GAAKMT2A | |
| SCHEMBL2833646 | 0.87 | MEN1 (0.45) | HSD11B1KMT2AMEN1EPHX2TDP1 | |
| SCHEMBL2833162 | 0.87 | MEN1 (0.45) | HSD11B1KMT2AMEN1EPHX2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017046581-A1 | COMPOSITION COMPRISING CAV2.2 CALCIUM CHANNEL BLOCKER AND OPIOID | CALCHAN LIMITED (GB) | 2017-03-23 | — | — | WO | claimed |
| WO-2017046581-A1 | COMPOSITION COMPRISING CAV2.2 CALCIUM CHANNEL BLOCKER AND OPIOID | CALCHAN LIMITED (GB) | 2017-03-23 | — | — | WO | disclosed |
| US-8536183-B2 | 3-pyridylcarbonyl-piperazinylsulfonyl derivatives | Convergence Pharmaceuticals Limited (GB) | 2013-09-17 | — | — | US | disclosed |
| US-20120302746-A1 | 3-PYRIDYLCARBONYL-PIPERAZINYLSULFONYL DERIVATIVES | BESWICK PAUL JOHN (GB) | 2012-11-29 | — | — | US | disclosed |
| US-8288388-B2 | 3-pyridylcarbonyl-piperazinylsulfonyl derivatives | Convergence Pharmaceuticals Limited (GB) | 2012-10-16 | — | — | US | disclosed |
| EP-2300432-B1 | PIPERAZINE DERIVATIVES USED AS CAV2.2 CALCIUM CHANNEL MODULATORS | CONVERGENCE PHARMACEUTICALS (GB) | 2012-10-03 | — | — | EP | disclosed |
| EP-2300432-A1 | PIPERAZINE DERIVATIVES USED AS CAV2.2 CALCIUM CHANNEL MODULATORS | Convergence Pharmaceuticals Limited (GB) | 2011-03-30 | — | — | EP | disclosed |
| US-20100022555-A1 | Novel Derivatives | Convergence Pharmaceuticals Limited (GB) | 2010-01-28 | — | — | US | disclosed |
| WO-2010007073-A1 | PIPERAZINE DERIVATIVES USED AS CAV2.2 CALCIUM CHANNEL MODULATORS | GLAXO GROUP LIMITED (GB) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022555-A1 | Novel Derivatives | CACNB2, CACNA1B, CACNA1D | HSD11B1 4779/4885ALDH1A1 3984/4885TRPV1 34/4885 |
| US-20120302746-A1 | 3-PYRIDYLCARBONYL-PIPERAZINYLSULFONYL DERIVATIVES | CACNB2, CACNA1C, KCNJ2 | HSD11B1 4873/4885ALDH1A1 3994/4885TRPV1 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.